Accolade, Inc. (NASDAQ:ACCD) is Fairman Group LLC’s 3rd Largest Position

Fairman Group LLC grew its position in shares of Accolade, Inc. (NASDAQ:ACCD) by 58.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,802,399 shares of the company’s stock after purchasing an additional 665,112 shares during the quarter. Accolade makes up about 5.1% of Fairman Group LLC’s holdings, making the stock its 3rd largest position. Fairman Group LLC owned 2.21% of Accolade worth $6,164,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Geode Capital Management LLC raised its holdings in shares of Accolade by 4.9% in the third quarter. Geode Capital Management LLC now owns 1,782,038 shares of the company’s stock valued at $6,862,000 after buying an additional 83,556 shares during the last quarter. Clearline Capital LP raised its stake in Accolade by 85.3% during the 3rd quarter. Clearline Capital LP now owns 1,539,578 shares of the company’s stock valued at $5,927,000 after acquiring an additional 708,794 shares during the last quarter. Whetstone Capital Advisors LLC acquired a new stake in Accolade during the 3rd quarter worth approximately $3,842,000. Point72 Asset Management L.P. purchased a new position in shares of Accolade in the 3rd quarter valued at approximately $2,378,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Accolade by 4.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 569,201 shares of the company’s stock valued at $2,191,000 after purchasing an additional 26,155 shares during the period. Institutional investors and hedge funds own 84.99% of the company’s stock.

Insider Transactions at Accolade

In related news, CEO Rajeev Singh sold 13,357 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $3.60, for a total value of $48,085.20. Following the completion of the sale, the chief executive officer now directly owns 814,316 shares in the company, valued at approximately $2,931,537.60. The trade was a 1.61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 40,145 shares of company stock valued at $157,917 over the last three months. Company insiders own 8.20% of the company’s stock.

Accolade Stock Down 0.3 %

ACCD stock opened at $6.87 on Wednesday. The firm has a 50 day simple moving average of $5.11 and a 200-day simple moving average of $4.27. Accolade, Inc. has a twelve month low of $3.08 and a twelve month high of $13.93. The company has a market capitalization of $560.50 million, a P/E ratio of -3.05 and a beta of 2.20. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 0.67.

Accolade (NASDAQ:ACCD) last released its quarterly earnings data on Friday, January 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.01. Accolade had a negative return on equity of 20.74% and a negative net margin of 40.36%. On average, equities research analysts predict that Accolade, Inc. will post -1.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ACCD has been the subject of several recent research reports. Leerink Partners reaffirmed a “market perform” rating on shares of Accolade in a report on Wednesday, January 8th. Stephens cut shares of Accolade from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Morgan Stanley dropped their price target on shares of Accolade from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Stifel Nicolaus restated a “hold” rating and issued a $7.03 price objective (down previously from $8.00) on shares of Accolade in a research report on Thursday, January 9th. Finally, Raymond James reiterated a “market perform” rating on shares of Accolade in a research report on Thursday, January 9th. Twelve equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $7.55.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.